Other News To Note

Idera Pharmaceuticals Inc., of Cambridge, Mass., said preclinical data showed that IMO-3100, an antagonist of Toll-like receptor 7 and TLR9, suppressed several key disease progression parameters in a model of lupus. The data, presented at the Dendritic Cells and Initiation of Adaptive Immunity Keystone Symposia, in Santa Fe, N.M., showed that IMO-3100 treatment led to a dose-dependent reduction in serum anti-DNA antibody levels, BUN levels and urine protein levels in NZBW/F1 mice.